In The News

Courage in Innovation: COI’s President and CEO, Jay Lichter, Named to PharmaVOICE 100

PharmaVOICE has named Jay Lichter, Ph.D., president and CEO of COI Pharmaceutical, to the magazine’s 2016 list of 100 outstanding professionals in the life-sciences industry.  Dr. Lichter was chosen as part of the group of visionary entrepreneurs who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.

Every year, PharmaVOICE receives thousands of nominations from readers for the most influential corporate leaders in their field. Candidates are selected based on their ability to inspire peers through their actions, as well as exhibiting strong leadership qualities, fearless and unique approaches to problems, and innovation in strategies, products and services.

Backed by Avalon Ventures, COI Pharmaceuticals is designed to be a unique venture-pharma incubator for early stage biotechnology companies – an area many investors have abandoned.  At the time of this award, Dr. Lichter has helped establish 14 companies within COI and assembled an outstanding and highly experienced team of leaders to manage and propel these drug development programs.  These companies were established to address a wide variety of unmet medical needs including ALS, celiac disease, cancer, and Graves’ disease.

Of the companies established at COI, eight have been formed under a unique agreement between Avalon Ventures and GSK. Established in 2013 and extended in 2015, this partnership was created to leverage COI’s nimble start-up mentality with GSK’s unparalleled R&D expertise and resources.

When colleagues were asked to comment on the impact of Dr. Lichter’s life-long efforts in the pharmaceutical and biotechonolgy space, PharmaVOICE reports, “Without courageous investors such as Dr. Lichter, the industry would eventually not be the source of improved human health.  At the same time, he applies just as much emphasis and empowerment to the individuality and capabilities of his management teams as he does to the technologies and business structure.”

Read the full profile of Dr. Litcher in the August issue of PharmaVoice.